218 results about "Hydroxybutyrates" patented technology

Compositions for inducing and maintaining a state of flow in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Compositions and methods for administering ketone bodies to a subject include beta-hydroxybutyrate complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

The invention relates to the technical field of degradable fibers, and discloses a degradable bamboo fiber composite material master batch and a preparation method thereof. The composite material is prepared from the following raw materials: modified bamboo fibers, modified polylactic acid, polyadipic acid / butylene terephthalate, a lubricant, an antioxidant and a plasticizer. The preparation method comprises the following steps: 1) performing alkali treatment and tannic acid-metal ion compound modification on the bamboo fibers to form a hydrophobic surface; 2) blending and modifying polylactic acid and bio-based elastomer polyhydroxybutyrate to construct a tough matrix; and 3) carrying out melt blending on the modified bamboo fiber, poly (adipic acid) / butylene terephthalate, the modified polylactic acid and an auxiliary agent, and then carrying out extrusion granulation. The degradable bamboo fiber composite material master batch prepared by the invention has good processability and mechanical properties, and can be widely applied to the fields of disposable tableware, packaging materials, agricultural plastic mulching films and the like.

The invention relates to the field of sponge materials, and provides an antibacterial degradable sponge material and a preparation method thereof. The material is prepared from protocatechuic acid modified quaternized chitosan, quaternary ammonium salt grafted gelatin, sodium alginate, polyhydroxybutyrate, polycaprolactone, a polylactic acid-glycolic acid copolymer, hexamethylene diisocyanate, a foaming agent, nano cellulose, vitamin E, polyethylene glycol, triethylamine and dimethylformamide. Protocatechuic acid and quaternized chitosan are subjected to amidation modification, and chitosan and gelatin are subjected to quaternization treatment by adopting 2, 3-epoxypropyl trimethyl ammonium chloride, so that the antibacterial property and biodegradability of the material are improved. In the material preparation process, through vacuum degassing, foaming vacuum degree and humidity control and a multi-step drying process, it is ensured that the average pore size of the material is uniform (50-200 microns) and the porosity is high (50%-90%), and the obtained material has excellent antibacterial property and degradability and has wide application value.

Compositions for inducing and maintaining a state of flow in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

Compositions for delivering ketone bodies to a subject include one or more beta-hydroxybutyrate salts, one or more acetoacetate salts, beta-hydroxybutyric acid, and optionally acetoacetic acid. The compositions may optionally include one or more ketone body esters, such as one or more beta-hydroxybutyrate esters and / or one or more acetoacetate esters. An example composition contains about 2% to about 98% on a molar basis of the one or more beta-hydroxybutyrate salts and the one or more acetoacetate salts, about 2% to about 98% on a molar basis of the beta-hydroxybutyrate free acid and optionally the acetoacetate free acid, and optionally about 2% to about 98% on a molar basis of one or more ketone body esters.

The invention provides a full-degradable polymer composite material for tableware and a preparation method of the full-degradable polymer composite material, and belongs to the technical field of polymer materials. According to the invention, amylose corn starch, hydrophobic modified corn starch, cassava acetylated distarch phosphate, a polylactic acid-poly (butylene succinate) interpenetrating network structure material, a copolymer of 3-hydroxybutyrate and 3-hydroxyvalerate, polycaprolactone, stearic acid modified micron titanium dioxide, chitosan quaternary ammonium salt and a composite plasticizer are adopted according to a specific ratio; the fully-degradable polymer composite material is obtained by compounding the composite heat stabilizer and stearic acid, has controllable and good biodegradability and good mechanical properties, enhances heat stability, improves processability, makes all the components easier to mix uniformly, facilitates molding processing of the material, and improves production efficiency and product quality.

The present embodiment relates to a biodegradable resin composition, a biodegradable film using the same, and a method for preparing the same, wherein the biodegradable resin composition comprises: a polylactic acid (PLA) resin; and a polyhydroxyalkanoate (PHA) resin. The PHA resin includes: a first PHA resin including a 3-hydroxyhexanoate (3HH) repeating unit; and a second PHA resin comprising a 4-hydroxybutyrate (4HB) repeating unit, thereby simultaneously improving the biodegradability, stretchability, and strength of the biodegradable film. Therefore, the biodegradable resin composition according to an embodiment of the present invention has excellent biodegradability and biocompatibility, and thus is environmentally friendly, and can ensure sufficient stretchability and strength thereof to produce a stretchable film, thereby being used for producing various products requiring moldability, and also being suitable for the production of various products requiring moldability. The present invention relates to a packaging material, such as a packaging material for disposable bags or food containers, and exhibits excellent properties.

Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

The invention provides a polyhydroxyalkanoate composition as well as a preparation method and application thereof. The polyhydroxyalkanoate composition comprises at least two kinds of copolymers of 3-hydroxybutyrate and 4-hydroxybutyrate. The at least two copolymers of 3-hydroxybutyrate and 4-hydroxybutyrate at least comprise one segmented copolymer of 3-hydroxybutyrate and 4-hydroxybutyrate, and in the segmented copolymer, the mass percentage content of a 4-hydroxybutyrate structural unit is 0-20%; the at least two copolymers of the 3-hydroxybutyrate and the 4-hydroxybutyrate at least comprise a random copolymer of the 3-hydroxybutyrate and the 4-hydroxybutyrate. The polyhydroxyalkanoate composition has good strength and toughness, the post-brittleness is also obviously improved, and meanwhile, the polyhydroxyalkanoate composition also has good processability and migration resistance.

The invention belongs to the technical field of biological medicines, and particularly relates to application of beta-hydroxybutyrate in preparation of a medicine for preventing or treating hepatocellular carcinoma. The invention provides an application of beta-hydroxybutyrate in preparation of a medicine for preventing and / or treating hepatocellular carcinoma. The beta-hydroxybutyrate comprises a beta-hydroxybutyrate or a combination of a plurality of beta-hydroxybutyrates. A series of experimental data show that beta-hydroxybutyrate not only can effectively improve fatty degeneration and inflammatory response of hepatocytes, but also can remarkably reduce the risk of occurrence of metabolic dysfunction related hepatocellular carcinoma (HCC), and can inhibit malignant biological characteristics of HCC. The invention provides a powerful scientific basis for the development of novel HCC prevention and treatment medicines, and has a wide clinical application prospect.

This extruded film contains a poly(3-hydroxyalkanoate)-based copolymer (A) and a poly(3-hydroxybutyrate) (B). The copolymer (A) preferably contains at least two types of poly(3-hydroxyalkanoate)-based copolymers having different constituent monomer types and / or constituent monomer content ratios. The copolymer (A) may include a copolymer (A-1) of a 3-hydroxybutyrate unit and another hydroxyalkanoate unit, wherein a content ratio of the other hydroxyalkanoate unit is 24 mol% or more.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Beta-hydroxybutyrate compositions formulated for ingestion by oral delivery as a beverage include a liquid carrier, such as water, milk, drinkable liquid, coconut water, watermelon water, or electrolyte water, and beta-hydroxybutyrate, wherein the beta-hydroxybutyrate can be enriched in R-beta-hydroxybutyrate relative to S-beta-hydroxybutyrate, wherein the beta-hydroxybutyrate comprises R-beta-hydroxybutyric acid, S-beta-hydroxybutyric acid, and optionally one or more salts or esters of R-beta-hydroxybutyrate and one or more salts or esters S-beta-hydroxybutyrate.

A method of protecting animal tissue particularly skin, from damage caused by radiation exposure, by contacting the tissue with a ketone ester, a method of protecting skin, reducing the deterioration of skin or maintaining or improving the properties of skin by applying topically to the skin a ketone body comprising (R)-3-hydroxybutyrate moieties is disclosed. A ketone body comprising (R)-3-hydroxybutyrate moieties, especially enantiomerically enriched R-1,3-hydroxybutyl-(R)-3-hydroxybutyrate, for such uses is also provided.

The invention discloses a full-degradable high-temperature-resistant foaming material which comprises a low-density system, a medium-density system and a high-density system, the low-density system comprises the following components: stereocomplex polylactic acid formed by mixing poly-L-lactic acid and poly-D-lactic acid, poly (butylene succinate), surface radiation modified straw fibers, talcum powder, nano clay and supercritical carbon dioxide; the medium-density system comprises the following components: stereocomplex polylactic acid formed by mixing poly-L-lactic acid and poly-D-lactic acid, poly (butylene succinate), plasticized starch, an AC foaming agent, zinc oxide and citric acid; the high-density system comprises the following components: stereocomplex polylactic acid formed by mixing poly-L-lactic acid and poly-D-lactic acid, polyhydroxybutyrate, surface radiation modified straw fibers, sodium bicarbonate and a DCP dynamic cross-linking agent. The full-degradable high-temperature-resistant foaming material provided by the invention has the advantages of high temperature resistance, good mechanical property, complete degradation and the like.

Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

The application provides a preparation method of piezoelectric nanofiber aerogel, comprising the following steps: S1, zinc oxide is added into hexafluoroisopropanol, polyhydroxybutyrate is added after ultrasonic dispersion, and magnetic stirring is conducted to obtain a PHB@ZnO solution; S2, the PHB@ZnO solution is prepared into a nanofiber membrane through electrospinning, the nanofiber membrane is placed into a vacuum drying box for vacuum drying to obtain a PHB@ZnO nanofiber membrane; S3, the PHB@ZnO nanofiber membrane is added into deionized water, and a short PHB@ZnO nanofiber dispersion liquid is obtained after homogenization; S4, chitosan powder is added into deionized water, glacial acetic acid is added after stirring, and chitosan solution is obtained after continuous stirring; S5, the short PHB@ZnO nanofiber dispersion liquid, the chitosan solution and glutaraldehyde are uniformly mixed to obtain a mixture, the mixture is poured into a mold, the mold is placed into a freeze dryer for freeze drying to obtain piezoelectric nanofiber aerogel. The piezoelectric nanofiber aerogel prepared by the piezoelectric nanofiber aerogel has a porous structure and good piezoelectric performance, and can accelerate bone defect repair.

A polyhydroxyalkanoate copolymer mixture is produced by culturing a microorganism. The mixture contains: a fraction (I) that contains a polyhydroxyalkanoate copolymer having 3-hydroxybutyrate structural units and 3-hydroxyhexanoate structural units and that has an average 3-hydroxyhexanoate content of 9 to less than 20 mol %; and a fraction (II) that contains a polyhydroxyalkanoate having 3-hydroxybutyrate structural units and that has an average 3-hydroxyhexanoate content of 0 to 8 mol %. The weight percentage of the fraction (II) in the polyhydroxyalkanoate copolymer mixture is 45% or more.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Methods to fabricate objects by 3D printing of poly-4-hydroxybutyrate (P4HIB) and copolymers thereof have been developed. In one method, these objects are produced by continuous fused filament fabrication using an apparatus and conditions that overcome the problems of poor feeding of the filament resulting from the low softening temperature of the filament and heat creep along the fed filament. Methods using an apparatus including a heat sink, a melt tube, a heating block and nozzle, and a transition zone between the heat sink and heating block, with the melt tube extending through the heat sink, transition zone, and heat block to the nozzle are disclosed. 3D objects are also printed by fused pellet deposition (FPD), melt extrusion deposition (MED), selective laser melting (SLM), printing of slurries and solutions using a coagulation bath, and printing using a binding solution and polymer granules.

A poly(3-hydroxyalkanoate) resin composition comprising: a copolymer (A) of 3-hydroxybutyrate units and other hydroxyalkanoate units, and a copolymer (B) of 3-hydroxybutyrate units and other hydroxyalkanoate units, wherein the content of other hydroxyalkanoate units in copolymer (A) is 1 to 6 mol%, and the content of other hydroxyalkanoate units in copolymer (B) is 24 mol% or more. The resin composition further comprises layered clay mineral (C). The proportion of (A) is 72 to 93 wt%, and the proportion of (B) is 7 to 28 wt%. The content of (C) is 5 to 45 parts by weight relative to 100 parts by weight of the total poly(3-hydroxyalkanoate) resin composition.

Provided is a resin tube containing a poly(3-hydroxyalkanoate)-based resin component. The resin component contains a poly(3-hydroxyalkanoate)-based resin (A) having a weight average molecular weight of 100,000 to 700,000 (exclusive of 700,000), and a copolymer (B) of a 3-hydroxybutyrate unit having a weight average molecular weight of at least 700,000 and another hydroxyalkanoate unit. The content ratio of the 3-hydroxybutyrate unit in the copolymer (B) is 76 mol% to 100 mol% (exclusive of 100 mol%). The content of the resin (A) in the total amount of the poly(3-hydroxyalkanoate)-based resin component is 80 wt% to 99 wt%, and the content of the copolymer (B) is 1 wt% to 20 wt%. The 50% fracture energy of the resin tube at 23°C is more than 0.625 J.

A process for the synthesis of poly-4-hydroxybutyrates is described, comprising the use of a kit of (i) one or more bases comprising alkali metal cations and (ii) one or more alcohols in said process, as well as the poly-4-hydroxybutyrates obtainable by said process.

Provided is a fiber containing a poly (3-hydroxyalkanoate)-based resin, the fiber containing a poly (3-hydroxyalkanoate)-based resin containing a 3-hydroxybutyrate unit, the fiber being suppressed in melt adhesion during the production of the fiber and being capable of being thermally fused under low-temperature conditions during thermal processing of the fiber. The present invention is a fiber having a core-sheath structure including a core part and a sheath part, the core part and the sheath part each containing a poly (3-hydroxyalkanoate)-based resin including a 3-hydroxybutyrate unit, the average molar content of 3-hydroxybutyrate units in the poly (3-hydroxyalkanoate)-based resin in the core part is greater than the average molar content of 3-hydroxybutyrate units in the poly (3-hydroxyalkanoate)-based resin in the sheath part.